All In Biotech

Drug Trial Radar · NCT06627231

Mass Balance Clinical Trial With TEV-56286

A Phase 1 Open-Label Mass Balance Clinical Trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants

Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Oct 8, 2024

Primary completion

Nov 29, 2024

Study completion Nov 29, 2024

Sponsor

Sponsor type
Industry
First posted
Oct 4, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Mass balance clinical trial with TEV-56286

Conditions

  • Healthy Participants

Interventions

  • TEV-56286Drug

    Oral capsule

  • [14C]-TEV-56286Drug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cumulative Amount of Total Radioactivity (TRA)Time frame: Up to Day 22
  2. Cumulative Percent of TRA From the Total Radioactive Dose AdministeredTime frame: Up to Day 22
  3. Maximum Observed Plasma Concentration (Cmax)Time frame: Up to Day 22
  4. Time to Attain Maximum Observed Plasma Concentration (Tmax)Time frame: Up to Day 22
  5. Area Under the Plasma Concentration-time Curve up to 24 Hours Postdose (AUC0-24)Time frame: Up to Day 22
  6. Area Under the Plasma Concentration-time Curve Up To Time t, Where t is the Last Point with Concentrations Above the Lower Limit of Quantification (AUC0-t)Time frame: Up to Day 22
  7. Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-∞)Time frame: Up to Day 22
  8. Terminal elimination half-life (t1/2)Time frame: Up to Day 22

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Teva Investigational Site 38189

    Groningen, Netherlands

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.